SuperworthAnavex Life Sciences EPS AVXL
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.15
- Latest quarter, Q3 FY26
- $0.08
- Fiscal year 2025
- −$0.54
Anavex Life Sciences' earnings per share was −$0.15 over the twelve months to Jun 30, 2026.
In its latest quarter, Q3 FY26, it was $0.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.54 | n/a |
| FY2024 | −$0.52 | n/a |
| FY2023 | −$0.60 | n/a |
| FY2020 | −$0.45 | n/a |
| FY2019 | −$0.54 | n/a |
| FY2018 | −$0.38 | n/a |
| FY2017 | −$0.28 | n/a |
| FY2016 | −$0.42 | n/a |
| FY2015 | −$0.59 | n/a |
| FY2014 | −$1.16 | n/a |
| FY2013 | −$0.40 | n/a |
| FY2012 | −$1.16 | n/a |
| FY2011 | −$1.08 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $0.08 | n/a | −$0.15 | |
| Q2 FY26 | −$0.06 | n/a | −$0.39 | |
| Q1 FY26 | −$0.06 | n/a | −$0.46 | |
| Q4 FY25 | −$0.11 | n/a | −$0.54 | |
| Q3 FY25 | −$0.16 | n/a | −$0.57 | |
| Q2 FY25 | −$0.13 | n/a | −$0.55 | |
| Q1 FY25 | −$0.14 | n/a | −$0.55 | |
| Q4 FY24 | −$0.14 | n/a | −$0.52 | |
| Q3 FY24 | −$0.14 | n/a | −$0.50 | |
| Q2 FY24 | −$0.13 | n/a | −$0.50 | |
| Q1 FY24 | −$0.11 | n/a | −$0.54 | |
| Q4 FY23 | −$0.12 | n/a | −$0.60 |
Against its peers
Companies in Healthcare nearest Anavex Life Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AVXLAnavex Life Sciences | −$0.15 | |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| SPROSpero Therapeutics | $0.11 | |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Anavex Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.